Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia

 

Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia

By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve …

More Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia Videos

Leave a Reply